Alexza Pharmaceuticals Revenue and Competitors

Claim your profile

Location

$185.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Alexza Pharmaceuticals's estimated annual revenue is currently $17.3M per year.(i)
  • Alexza Pharmaceuticals's estimated revenue per employee is $201,000
  • Alexza Pharmaceuticals's total funding is $185.7M.

Employee Data

  • Alexza Pharmaceuticals has 86 Employees.(i)
  • Alexza Pharmaceuticals grew their employee count by -1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$54.7M27235%N/AN/A
#2
$1.2M6N/AN/AN/A
#3
$26.3M1313%N/AN/A
#4
N/A1240%$62.5MN/A
#5
$21.9M10910%N/AN/A
#6
$137.5M684-4%N/AN/A
#7
$14.9M8616%$173MN/A
#8
$91.3M454N/AN/AN/A
#9
$64.5M321-7%N/AN/A
#10
$9.4M470%N/AN/A

Alexza MDC was founded in 2000 and has been backed by Alex Zaffaroni,Ph.D., who transformed Syntex into a major pharmaceutical company and founded ALZA Corporation, the pioneering drug delivery company acquired by Johnson & Johnson in 2001. He has also founded a variety of leading companies, including Affymax, Affymetrix, Maxygen, Surromed and Symyx.

keywords:N/A

$185.7M

Total Funding

86

Number of Employees

$17.3M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alexza Pharmaceuticals News

2022-04-20 - Acute Repetitive Seizures Market Growth 2022-2030| Key ...

Alexza Pharmaceuticals; Veriton Pharma. Acute Repetitive Seizures Market Breakdown by Type: USL-261; NRL-1; Diastat Rectal Gel; Others.

2022-04-19 - Acute Repetitive Seizures Drugs Market Size, Share, Growth ...

Union Chimique Belge (UCB); Neurelis; Bausch Health; Alexza Pharmaceuticals; Veriton Pharma. Acute Repetitive Seizures Drugs Market Breakdown by...

2022-04-17 - Epileptic Seizures Treatment Market is Booming Worldwide ...

... Inc., GlaxoSmithKline plc., UCB S.A., Pfizer, Inc., Apotex, Inc., Alexza Pharmaceuticals, Inc., Neurelis, Inc., Veriton Pharma.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.8M88100%N/A
#2
$14.1M8876%N/A
#3
$12.5M89178%$15.2M
#4
$25.8M896%N/A
#5
$12.6M901%$20.5M